As part of SurvivorNet Connect’s ongoing special series “Cancer Dialogues”, four of the nation’s leading neuro-oncologists gathered in Honolulu to discuss timely news items on the latest treatments for glioma, as well as remaining questions about which glioma patients are eligible for specific treatments.
During the panel discussion, the experts spotlighted emerging advances in glioma treatment. Dr. Rimas V. Lukas from Northwestern University Feinberg School of Medicine identified the FRONTIER Trial as particularly compelling for its exploration of therapies in central nervous system disease. Dr. Katherine Peters of Duke University’s Preston Robert Tisch Brain Tumor Center discussed vorasidenib and related inhibitors, highlighting their potential to benefit glioma patients across disease stages.
